Literature DB >> 342621

Antibody responses and reactogenicity of graded doses of inactivated influenza A/New Jersey/76 whole-virus vaccine in humans.

.   

Abstract

Graded doses of inactivated whole influenza A/New Jersey/8/76 virus vaccine were injected into healthy volunteers. Presence of hemagglutination-inhibiting (HAI) antibody was uncommon before vaccination in persons younger than 45 years and most common in those older than 65 years. All vaccine doses (4-61 microgram of hemagglutinin) induced HAI antibody in at least 50% of recipients, although a booster dose was required to induce high titers in those younger than 24 years of age. A tendency for HAI titers to increase with increasing age and dose was noted. A trivalent vaccine (composed of A/New Jersey/76, A/Victoria/75, and B/Hong Kong/73) given to persons 21-44 years old produced HAI antibody titers to A/New Jersey/76 similar to those produced by the same dose of A/New Jersey/76 as a monovalent vaccine and produced higher titers in subjects 65 years of age or older. Increases in neuraminidase-inhibiting antibody were small and infrequent. Local and system symptoms were commonly reported after vaccination but were mostly mild (11% had moderate pain and 19% had muscular aches). Reactions were less common among those with HAI antibody at the time of vaccination and were unacceptably severe (in 20% of recipients) only in seronegative recipients given the 61-microgram dose of hemagglutinin.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 342621     DOI: 10.1093/infdis/136.supplement_3.s475

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

1.  Use of the enzyme-linked immunosorbent assay (ELISA) for the estimation of serum antibodies in an influenza virus vaccine study.

Authors:  R Jennings; T Smith; C W Potter
Journal:  Med Microbiol Immunol       Date:  1981       Impact factor: 3.402

2.  A multi-valent vaccine approach that elicits broad immunity within an influenza subtype.

Authors:  Victor C Huber; Paul G Thomas; Jonathan A McCullers
Journal:  Vaccine       Date:  2009-01-07       Impact factor: 3.641

3.  A review of influenza vaccine immunogenicity and efficacy in HIV-infected adults.

Authors:  Curtis Cooper; Brian Hutton; Dean Fergusson; Edward Mills; Marina B Klein; Guy Boivin; Scott Halperin
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-11       Impact factor: 2.471

4.  Refining the approach to vaccines against influenza A viruses with pandemic potential.

Authors:  Rita Czako; Kanta Subbarao
Journal:  Future Virol       Date:  2015       Impact factor: 1.831

Review 5.  Influenza: the virus and prophylaxis with inactivated influenza vaccine in "at risk" groups, including COPD patients.

Authors:  Arnt-Ove Hovden; Rebecca Jane Cox; Lars Reinhardt Haaheim
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

Review 6.  Confronting the avian influenza threat: vaccine development for a potential pandemic.

Authors:  Iain Stephenson; Karl G Nicholson; John M Wood; Maria C Zambon; Jacqueline M Katz
Journal:  Lancet Infect Dis       Date:  2004-08       Impact factor: 25.071

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.